Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sen. Kohl fights for more FDA funding

This article was originally published in The Tan Sheet

Executive Summary

FDA would receive $275 million additional funding this year to address import safety oversight, improve its information technology systems and implement new safety initiatives under an amendment Sen. Herb Kohl, D-Wis., chairman of the FDA appropriations subcommittee, added to the fiscal 2008 emergency war funding/supplemental appropriations bill passed by the House, H.R. 2764. The bill is slated for May 15 Senate Appropriations Committee markup. Of the total, $100 million is allocated to drug and medical device safety activities, $125 million will go to food safety activities and $40 million will be put towards modernizing FDA science and its workforce, issues considered at an April committee hearing ("The Tan Sheet," April 21, 2008, p. 5). Kohl said the additional funding would support efforts including opening two FDA offices overseas; implementing pediatric drug safety; and hiring 99 medical product safety inspectors...

You may also be interested in...



FDA could use more appropriations

FDA could absorb an additional $100 million in funding over that proposed by the Bush Administration for fiscal 2009, but not the full $375 million recommended by the FDA Science Board, Commissioner Andrew von Eschenbach tells the Senate Appropriations Committee at an April 15 hearing. "We could absorb the $100 million that you referred to, and do that quite rapidly and quite effectively," he told the panel. "As we would get closer and closer to the [$375 million] ... it would require greater stewardship to be sure we could implement those dollars as rapidly and effectively as we need to," he said. The administration's proposal provides a $51 million increase over 2008 in direct appropriations to FDA, bringing federal funding to $1.77 billion in FY 2009 (1"The Pink Sheet," Feb. 11, 2008, p. 4). "It may be our responsibility to fix OMB's mistake here. And you probably have more friends here than you might have at other places in town," Sen. Robert Bennett, R-Utah., told the commissioner. An amendment sponsored by Sen. Ted Kennedy, D-Mass., would increase FDA appropriations according to the Science Board's recommendations for a $375 million increase over fiscal 2008 in direct appropriations to FDA for 2009, and larger increases in each of the following five years (2"The Pink Sheet," March 3, 2008, p. 9)

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.

Shuttered US Supplement Firm Meets Recall Deadline, But Schumer Says FDA Late Cleaning Up Industry

While contract manufacturer ABH Nature' complied with consent decree, Sen. Chuck Schumer says FDA is late in enforcing against noncompliant firms across the supplement sector. Other recent consumer health recalls include more OTC ranitidine tablets due to the potential carcinogen NDMA found in the heartburn ingredient and four versions of Sure 48HR Anti-Perspirant & Deodorant with labeling errors.

Topics

UsernamePublicRestriction

Register

PS101655

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel